Tonghua Golden-Horse Pharmaceutical Industry Co 000766.SZ · CNY
Health Care · Shenzhen · 🇨🇳 China
14.20
-2.81%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Tonghua Golden-Horse Pharmaceutical Industry Co
Its shares trade on Shenzhen under the ticker 000766.SZ. It has been listed since 30 April 1997. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.17bn and net income of CN¥34.3m. At that date it held total assets of CN¥4.48bn and shareholders' equity of CN¥2.31bn.
Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products. The company is headquartered in Tonghua, Jilin. The firm's main products consist of Chinese patent drugs, chemical drugs and bulk drugs, among others. The Company’s products are used in anti-tumor, microbial, digestive system, skeletal and muscle system, gynecology, nervous system and other areas. The firm distributes its products mainly in domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 30 Apr 1997
- Employees
- 1,696
- Website
- thjm.cn ↗
Leadership
Pay as last reported
- Mr. Yufu ZhangChairman of the Board, General Manager, since 2019CN¥828,000
- Mr. Jun YuChief Financial Officer, Deputy General Manager, Director, since 2006CN¥360,000
- Mr. Yu JingChief Marketing Officer, Deputy General ManagerCN¥360,000
- Ms. Haoyan ZhangGeneral Manager, Director, since 2023
- Mr. Huan WangDeputy General Manager, Director, since 2019
- Mr. Xiaolang YuDeputy General ManagerCN¥480,000
- Mr. Hailong ZhangExecutive Deputy General ManagerCN¥72,000
- Mr. Weilin JiaSecretary of the BoardCN¥360,000
- Ms. Yingjie WeiDirector
- Mr. Qiang ZhouDirector
- Ms. Jiajun HanIndependent Director
- Ms. Guixia LuIndependent DirectorCN¥50,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Tonghua Golden-Horse employs 1,696 full-time employees for pharmaceutical R&D and production.
- The company focuses on Chinese patent drugs and chemical drugs for anti-tumor and digestive systems.
- Domestic market distribution ensures strong presence in China's pharmaceutical sector.
Weaknesses
- Limited international market presence restricts global expansion opportunities.
- Dependence on domestic market may increase vulnerability to local economic fluctuations.
- No mention of international distribution channels or global partnerships.
Opportunities
- Growing demand for Chinese patent drugs in domestic healthcare systems.
- Expansion into skeletal and muscle system drug markets within China.
- Potential for increased sales in nervous system and gynecology drug segments.
Threats
- Competition from domestic pharmaceutical firms in China's crowded market.
- Regulatory changes in China's healthcare sector could impact operations.
- Economic downturns in China may reduce healthcare spending.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.